Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 3.78B 556M 486M 448M 414M 788M 53.06B 803M 5.37B 2.1B 26.12B 2.09B 2.04B 90.34B P/E 2024
217x
P/E 2025 322x
Enterprise Value 4.64B 683M 597M 551M 509M 967M 65.14B 985M 6.6B 2.58B 32.07B 2.56B 2.51B 111B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.07%
Yield 2024
0.37%
Yield 2025 0.06%
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-06 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
25-10-29 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-10-13 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25-08-25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-07-02 Realcan Pharmaceutical Vice President Detained MT
25-07-02 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25-06-03 Yanquan No. 8 Private Securities Investment Fund, a fund managed by Jiaxing Yanquan Investment Partnership LLP cancelled the acquisition of 5.05% stake in Realcan Pharmaceutical Group Co., Ltd. from Zhang Renhua for approximately CNY 160 million. CI
25-06-03 Realcan Pharmaceutical Group Shareholder Nixes Share Transfer Deal MT
1 day-0.77%
1 week-0.39%
Current month+4.47%
1 month-6.20%
3 months-24.85%
6 months-23.28%
Current year-20.19%
1 week 2.52
Extreme 2.52
2.68
1 month 2.38
Extreme 2.38
2.81
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 2021-04-25
President 61 2023-05-25
Corporate Officer/Principal 40 2019-10-29
Director TitleAgeSince
Chairman 61 2009-11-20
Director/Board Member 43 2009-11-20
Director/Board Member 71 2023-05-18
Date Insider Type Main position Quantity % Market Cap.
23-05-11Sell

Founder

15,000,000 1.2902%
23-03-29Sell

Founder

13,040,000 1.1260%
23-03-29Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%-0.39%-14.33%-23.96% 560M
-3.16%+3.22%+9.49%+91.13% 95.85B
-1.43%-1.66%+42.15%+148.77% 55.54B
+2.50%+4.74%-4.01%+250.00% 22.26B
-0.56%+2.68%-10.67%-25.36% 8.02B
-0.41%-2.57%-26.54%-36.83% 7.46B
-3.03%+4.71%-9.65%-30.15% 6.84B
-1.29%+0.05%+21.14%+35.58% 6.37B
+0.81%+2.66%-0.80%+24.04% 5.31B
-0.20%+5.93%-4.76%-6.52% 3.67B
Average -0.75%+1.52%+0.20%+42.67% 21.19B
Weighted average by Cap. -1.70%+3.77%+13.77%+104.76%

Financials

2024 2025
Net sales 7.97B 1.17B 1.03B 946M 874M 1.66B 112B 1.69B 11.33B 4.44B 55.07B 4.4B 4.31B 190B 7.3B 1.07B 939M 866M 800M 1.52B 102B 1.55B 10.38B 4.06B 50.44B 4.03B 3.95B 174B
Net income 20.62M 3.04M 2.65M 2.45M 2.26M 4.3M 290M 4.38M 29.33M 11.49M 143M 11.4M 11.15M 493M 16.07M 2.37M 2.07M 1.91M 1.76M 3.35M 226M 3.41M 22.86M 8.95M 111M 8.88M 8.69M 384M
Net Debt 1.6B 235M 205M 189M 175M 333M 22.4B 339M 2.27B 889M 11.03B 882M 863M 38.15B 860M 127M 111M 102M 94.37M 179M 12.08B 183M 1.22B 479M 5.95B 476M 465M 20.57B
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
26-07-09 CN¥2.570 -0.77% 31,104,568
26-07-08 CN¥2.590 +1.17% 25,053,967
26-07-07 CN¥2.560 -3.76% 28,844,190
26-07-06 CN¥2.660 +0.76% 30,615,067
26-07-03 CN¥2.640 +1.93% 37,482,100
  1. Stock Market
  2. Stocks
  3. 002589 Stock